North Creek Pharms

North Creek Pharmaceuticals was a specialty pharmaceutical company based in Bothell, Washington, focused on developing treatments for rare and orphan diseases, particularly in the field of ophthalmology. The company's lead candidate, NCP-101 (propanamidine isethionate), was being developed for the treatment of Acanthamoeba keratitis, a rare but severe parasitic infection of the cornea. In 2013, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to NCP-101, recognizing the significant unmet need in this patient population. The company was founded by industry veterans with experience from ICOS Corporation and Eli Lilly. While it made progress in the early 2010s, the company currently appears to be inactive. North Creek Pharmaceuticals is distinct from the cannabis producer North Creek Pharms also located in Washington.